| Description: |
Jingzhe Zhao,1,* Xiaoshan Luo,2,* Huan Li,1 Yu Cheng,1 Xiangping Lin3,* Su Xie,4,*1Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, Guizhou, People’s Republic of China; 2Traditional Chinese Medical Department, Zunyi Medical and Pharmaceutical College, Zunyi, Guizhou, People’s Republic of China; 3Department of Pharmacy, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People’s Republic of China; 4Department of Traditional Chinese Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Su Xie, Department of Traditional Chinese Medicine, Affiliated Hospital of Guizhou Medical University, No. 16 Beijing Road, Yunyan District, Guiyang, Guizhou, 550004, People’s Republic of China, Tel +86 0851 86773643, Email xiesutcm@163.com Xiangping Lin, Department of Pharmacy, Affiliated Hospital of Guizhou Medical University, No. 16 Beijing Road, Yunyan District, Guiyang, Guizhou, 550004, People’s Republic of China, Tel +86 0851 86774148, Email linxiangping@gmc.edu.cnBackground: Triple-negative breast cancer (TNBC) is clinically characterized by the absence of therapeutic targets and limited treatment options after surgery, leading to poor therapeutic outcomes and prognosis. Shuyu Pills (SYP), a classical traditional Chinese medicine (TCM) formula for treating deficiency syndromes with pathogenic excess, has been widely applied in the treatment of TNBC. However, its mechanisms of action against TNBC remain unclear.Purpose: This study aimed to investigate the anti-tumor effect and the underlying mechanisms of SYP in combination with the mTOR inhibitor everolimus in TNBC both in vitro and in vivo experiments.Methods: Network pharmacology was used to predict the potential signaling pathways targeted by SYP. The pharmacological effects of SYP and its combination with everolimus were evaluated through in ... |